End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.191 RON | +2.69% | +0.53% | -4.50% |
2023 | S.C. Ropharma S.A. Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
2023 | S.C. Ropharma S.A. Reports Earnings Results for the Full Year Ended December 31, 2022 | CI |
Valuation
Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Capitalization 1 | 188.1 | 178.9 | 140.6 | 117.2 | 106 | 95.61 |
Enterprise Value (EV) 1 | 212.1 | 237.2 | 274.2 | 248.6 | 232.2 | 228.5 |
P/E ratio | 16.2 x | 14.7 x | 19.1 x | 17.4 x | - | 10.4 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | 0.35 x | 0.28 x | 0.18 x | 0.15 x | 0.12 x | 0.1 x |
EV / Revenue | 0.4 x | 0.37 x | 0.35 x | 0.31 x | 0.26 x | 0.23 x |
EV / EBITDA | 9.61 x | 11.2 x | 14.5 x | 9.92 x | 7.4 x | 9.45 x |
EV / FCF | -6.94 x | 38.9 x | -27.4 x | -33.7 x | -65.2 x | 22.1 x |
FCF Yield | -14.4% | 2.57% | -3.65% | -2.96% | -1.53% | 4.53% |
Price to Book | 1.17 x | 1.03 x | 0.79 x | 0.59 x | - | 0.41 x |
Nbr of stocks (in thousands) | 511,267 | 511,267 | 498,499 | 509,742 | 509,736 | 511,267 |
Reference price 2 | 0.3680 | 0.3500 | 0.2820 | 0.2300 | 0.2080 | 0.1870 |
Announcement Date | 18-04-26 | 19-04-25 | 20-04-30 | 21-04-28 | 22-04-28 | 23-04-27 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Net sales 1 | 534.8 | 636.2 | 783.7 | 805.9 | 888.2 | 1,002 |
EBITDA 1 | 22.06 | 21.23 | 18.89 | 25.06 | 31.36 | 24.18 |
EBIT 1 | 13.08 | 11.59 | 8.701 | 10.55 | 17.11 | 9.256 |
Operating Margin | 2.45% | 1.82% | 1.11% | 1.31% | 1.93% | 0.92% |
Earnings before Tax (EBT) 1 | 15.21 | 14.76 | 6.689 | 6.637 | 13.53 | 10.32 |
Net income 1 | 11.63 | 12.12 | 7.523 | 6.753 | 10.73 | 9.216 |
Net margin | 2.17% | 1.9% | 0.96% | 0.84% | 1.21% | 0.92% |
EPS 2 | 0.0227 | 0.0237 | 0.0148 | 0.0132 | - | 0.0180 |
Free Cash Flow 1 | -30.58 | 6.104 | -10 | -7.366 | -3.56 | 10.35 |
FCF margin | -5.72% | 0.96% | -1.28% | -0.91% | -0.4% | 1.03% |
FCF Conversion (EBITDA) | - | 28.74% | - | - | - | 42.8% |
FCF Conversion (Net income) | - | 50.36% | - | - | - | 112.29% |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 18-04-26 | 19-04-25 | 20-04-30 | 21-04-28 | 22-04-28 | 23-04-27 |
Balance Sheet Analysis
Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Net Debt 1 | 23.9 | 58.2 | 134 | 131 | 126 | 133 |
Net Cash position 1 | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | 1.085 x | 2.743 x | 7.076 x | 5.241 x | 4.022 x | 5.496 x |
Free Cash Flow 1 | -30.6 | 6.1 | -10 | -7.37 | -3.56 | 10.3 |
ROE (net income / shareholders' equity) | 8.26% | 7.17% | 2.53% | 2.37% | 5.49% | 3.31% |
ROA (Net income/ Total Assets) | 2.41% | 1.71% | 0.93% | 1% | 1.62% | 0.8% |
Assets 1 | 483.2 | 710.4 | 805.7 | 678.7 | 661.5 | 1,145 |
Book Value Per Share 2 | 0.3100 | 0.3400 | 0.3600 | 0.3900 | - | 0.4500 |
Cash Flow per Share 2 | 0.0200 | 0.0200 | 0.0200 | 0.0300 | - | 0.0300 |
Capex 1 | 17.1 | 16.4 | 27 | 12 | 17.6 | 10.4 |
Capex / Sales | 3.2% | 2.57% | 3.44% | 1.49% | 1.99% | 1.04% |
Announcement Date | 18-04-26 | 19-04-25 | 20-04-30 | 21-04-28 | 22-04-28 | 23-04-27 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
-4.50% | 20.57M | |
-16.15% | 3.47B | |
-5.36% | 3.22B | |
-22.81% | 3.11B | |
+7.98% | 2.71B | |
-9.42% | 1.76B | |
+12.23% | 1.41B | |
-17.17% | 1B | |
-36.81% | 724M | |
-0.53% | 461M |
- Stock Market
- Equities
- RPH Stock
- Financials S.C. Ropharma S.A.